Resources from the same session
LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801
Presenter: Sapna Patel
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA49 - mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response
Presenter: Jeffrey Weber
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1081O - ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)
Presenter: Meredith Mckean
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Webcast
1082O - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)
Presenter: Isabella Glitza
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1085O - Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)
Presenter: Elizabeth Burton
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1082O and 1085O
Presenter: Reinhard Dummer
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Melanoma and other skin tumours
Resources:
Webcast